Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.190
-0.050 (-2.23%)
At close: Apr 28, 2026, 4:00 PM EDT
2.174
-0.016 (-0.75%)
After-hours: Apr 28, 2026, 7:44 PM EDT
Daré Bioscience Employees
As of December 31, 2025, Daré Bioscience had 24 total employees, including 21 full-time and 3 part-time employees. The number of employees increased by 1 or 4.35% compared to the previous year.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$42,925
Profits / Employee
-$558,303
Market Cap
31.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| NextCure | 40 |
| Senti Biosciences Holdings | 34 |
| Boundless Bio | 28 |
| Outlook Therapeutics | 17 |
| CervoMed | 15 |
DARE News
- 4 weeks ago - Daré Bioscience Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - On National Viagra Day, Women Finally Claim Their Turn: - GlobeNewsWire
- 6 weeks ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - GlobeNewsWire
- 6 weeks ago - Daré Bioscience Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 4 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 5 months ago - Daré Bioscience Earnings Call Transcript: Q3 2025 - Transcripts